Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMMNC intracoronary infusion after acute myocardial infarction
NL-OMON46907Phase 3Active, not recruiting
- Sponsor
- Queen Mary University of London
- Start
- Mar 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous bone marrow-derived mononuclear cell in myocardial infarction (MI) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: All-cause death. Started Mar 2016; status: active, not recruiting.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON46907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46907.